Asthma market to remain stable over next decade, despite generic erosion – The Pharma Letter


The Pharma Letter

Asthma market to remain stable over next decade, despite generic erosion
The Pharma Letter
New market potential in underserved asthma population: Emerging anticytokines that are predicted to launch during the next decade will serve part of the unmet need in the severe, refractory asthma population, which is currently served by only systemic …

View full post on asthma – Google News

Prospect of generic asthma drug Advair hits Glaxo – Philly.com


The West Australian

Prospect of generic asthma drug Advair hits Glaxo
Philly.com
GlaxoSmithKline P.L.C.'s top-selling drug by far is the asthma medication Advair, which accounts for about 20 percent of company revenue, but generic competition got a bit closer to reality this week. Advair is delivered to patients through an inhaler
Mylan shares jump after FDA lays out guidelines for asthma genericMarketWatch (blog)
FDA Offers Guidance for Advair KnockoffsWall Street Journal
Glaxo May Face Generic Advair Sooner Than ExpectedForbes
Chicago Tribune –PMLiVE –FiercePharma
all 24 news articles »

View full post on asthma – Google News

Mylan shares jump after FDA lays out guidelines for asthma generic – MarketWatch (blog)


Philly.com (blog)

Mylan shares jump after FDA lays out guidelines for asthma generic
MarketWatch (blog)
Shares of Mylan Inc. jumped nearly 5% in mid-afternoon trades on Tuesday after it became clear the U.S. Food and Drug Administration's guidelines on generic forms of GlaxoSmithKline's asthma medication Advair would work in favor of Mylan, considered a 
FDA issues generic guidance on GSK's top-selling asthma drug, AdvairPhilly.com (blog)
GlaxoSmithKline Shares Fall After Advair SetbackWall Street Journal
GSK shares hit as Advair generic threat grows in USChicago Tribune
Financial Times –FiercePharma
all 16 news articles »

View full post on asthma – Google News

FDA issues generic guidance on GSK’s top-selling asthma drug, Advair – Philly.com (blog)


Yahoo!7 News

FDA issues generic guidance on GSK's top-selling asthma drug, Advair
Philly.com (blog)
PhillyPharma. FDA issues generic guidance on GSK's top-selling asthma drug, Advair. GlaxoSmithKline's top-selling drug by far is the asthma medication Advair, which accounts for about 20 percent of company revenue. Generic competition got a bit closer
GlaxoSmithKline Shares Fall After Advair SetbackWall Street Journal
Glaxo Declines as FDA Clears Path for Advair RivalsBloomberg
New FDA guidance threatens GlaxoSmithKline's AdvairFiercePharma
euronews
all 13 news articles »

View full post on asthma – Google News

In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin’s … – Business Wire (press release)

In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin's
Business Wire (press release)
The upcoming Pharmacor advisory service entitled Asthma, which will be published soon, also finds that the overall market for asthma therapies will be relatively flat over the next decade, with sales increasing slightly by approximately $200 million

and more »

View full post on asthma – Google News

In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin’s … – MarketWatch (press release)

In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin's
MarketWatch (press release)
The upcoming Pharmacor advisory service entitled Asthma, which will be published soon, also finds that the overall market for asthma therapies will be relatively flat over the next decade, with sales increasing slightly by approximately $200 million

and more »

View full post on asthma – Google News

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Washington Post


Proactive Investors USA & Canada

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma
Washington Post
Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia beat Wall Street's
Merck tops view, newer drugs cushion asthma drug blowGlobe and Mail
Merck Q3 earnings edge up despite decline in salesProactive Investors USA & Canada
Merck's Profit Rises 2.2%Wall Street Journal
Chicago Tribune –Fox Business
all 221 news articles »

View full post on asthma – Google News

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Newser


Globe and Mail

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma
Newser
The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based in Whitehouse Station, N.J
Merck tops view, newer drugs cushion asthma drug blowGlobe and Mail
Merck posts mixed results for third quarterChicago Tribune
MERCK & CO., INC. : Merck 3rd-Quarter Profit Up 2.2%; Narrows Year View4-traders
Fox Business –The Markets Are Open (blog)
all 161 news articles »

View full post on asthma – Google News